Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Abecma Approved for Earlier Lines of MM Therapy in Japan: BMS
December 7, 2023
- Pfizer to Cut Ties with 3 Regional Wholesalers, Further Narrowing Expected
December 5, 2023
- Shionogi Hooks Up with Life Science VC AN Venture Partners
December 5, 2023
- Preliminary Injunction for Sprycel Generic “Extremely Unjust”: Sawai
December 5, 2023
- Ono Doubles Investment in Corporate Venture Fund to US$200 Million
December 4, 2023
- Padcev/Keytruda Combo Gets FDA Priority Review for Bladder Cancer
December 4, 2023
- Torii, BioCryst Revise Deal for HAE Drug Orladeyo in Japan
December 1, 2023
- Eisai Unit Joins Hands with Thai Authorities on Dementia Drug Access
December 1, 2023
- Mitsubishi Tanabe’s NMOSD Drug Uplizna Now Available in Taiwan
December 1, 2023
- Teijin Earns Japan Rights to 3 Hormone Therapies from Denmark’s Ascendis
November 30, 2023
- Sawai Slapped with Preliminary Injunction for Sprycel Generic over CML Use
November 30, 2023
- Ying Chen to Helm Bayer Yakuhin from January
November 30, 2023
- Bayer Set to Continue Stepping Up External Collaborations to Develop New Drugs: Regional BD Chief
November 30, 2023
- Sawai, Towa See Double-Digit Growth in H1, but Stick to Full-Year Forecasts amid Uncertainties
November 29, 2023
- Meiji Set to Start Supplying COVID Jab in Japan Next Fall-Winter
November 29, 2023
- Debut of Japan-Made COVID-19 Jab Is Momentous: Daiichi Sankyo President
November 29, 2023
- Rystiggo Now Available for gMG Patients in Japan: UCB
November 29, 2023
- Amylyx Sets Up Japan Arm to Bring ALS Drug across Pacific
November 28, 2023
- UCB Japan Gathers Pace in Rare Disease Space with 2 New Launches for gMG
November 28, 2023
- Taisho to Go Private through MBO in a Pivot to Longer-Term Strategies
November 28, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…